For the one million people diagnosed with Parkinson's disease in the United States, Medtronic plc (NYSE:MDT), a global leader in healthcare technology, proudly announces U.S. Food and Drug ...

For the one million people diagnosed with Parkinson's disease in the United States1, Medtronic plc (NYSE:MDT), a global ...

Medtronic (MDT) announced FDA approval of BrainSense Adaptive deep brain stimulation – aDBS – and BrainSense Electrode Identifier. There is no cure for debilitating neurological conditions like ...

The FDA approves BrainSense Adaptive deep brain stimulation and electrode identifier technology for the treatment of ...

The biggest technical challenge for adaptive deep brain stimulation (aDBS) is how small brain signals are, Medtronic's Scott ...

Medtronic gets US FDA nod for the world’s first adaptive deep brain stimulation system for people with Parkinson’s disease: Galway, Ireland Saturday, March 1, 2025, 09:00 Hrs ...

The FDA has approved BrainSense, an adaptive deep brain stimulation system that can adjust therapy for Parkinson’s disease in ...

Bullish option flow detected in Medtronic (MDT) with 13,596 calls trading, 3x expected, and implied vol increasing over 1 point to 19.29%.

The FDA has approved Medtronic's Brainsense Adaptive deep brain stimulation for patients with Parkinson's disease. The technology is designed to adjust therapy in real time based on a patient's brain ...